142 related articles for article (PubMed ID: 16022164)
1. Statistical consideration of adaptive methods in clinical development.
Chow SC; Chang M; Pong A
J Biopharm Stat; 2005; 15(4):575-91. PubMed ID: 16022164
[TBL] [Abstract][Full Text] [Related]
2. Inference for clinical trials with some protocol amendments.
Chow SC; Shao J
J Biopharm Stat; 2005; 15(4):659-66. PubMed ID: 16022170
[TBL] [Abstract][Full Text] [Related]
3. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
4. Review of draft FDA adaptive design guidance.
Cook T; DeMets DL
J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
[TBL] [Abstract][Full Text] [Related]
5. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
[TBL] [Abstract][Full Text] [Related]
6. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
Liu Q; Chi GY
J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
[TBL] [Abstract][Full Text] [Related]
7. Meta-analyses and adaptive group sequential designs in the clinical development process.
Jennison C; Turnbull BW
J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162
[TBL] [Abstract][Full Text] [Related]
8. Adaptive design methods in clinical trials - a review.
Chow SC; Chang M
Orphanet J Rare Dis; 2008 May; 3():11. PubMed ID: 18454853
[TBL] [Abstract][Full Text] [Related]
9. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
10. Statistical inference for clinical trials with binary responses when there is a shift in patient population.
Yang LY; Chi Y; Chow SC
J Biopharm Stat; 2011 May; 21(3):437-52. PubMed ID: 21442518
[TBL] [Abstract][Full Text] [Related]
11. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
12. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
13. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
14. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
Cheng B; Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
[TBL] [Abstract][Full Text] [Related]
15. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
[TBL] [Abstract][Full Text] [Related]
16. Confidence intervals and controlled clinical trials: incompatible tools for medical research.
Hall DB
J Biopharm Stat; 1993 Sep; 3(2):257-63. PubMed ID: 8220408
[TBL] [Abstract][Full Text] [Related]
17. Innovative approaches in drug development.
Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
[TBL] [Abstract][Full Text] [Related]
18. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
Sagkriotis A; Scholpp J
Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
[TBL] [Abstract][Full Text] [Related]
19. A note on special articles on adaptive clinical trial designs.
Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
[No Abstract] [Full Text] [Related]
20. FDA signals it's open to drug trials that shift midcourse.
Mathews AW
Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
